Jerry Martin
Jerry Martin is Senior Vice President and Global Technical Director, Biopharmaceuticals at PALL Life Sciences.
Articles
Reducing the risk of microbial contamination
February 1st 2010Maintaining asepsis and sterility is the primary challenge to implementing aseptic techniques and sterile processes in biopharmaceutical manufacture. Efforts to reduce the risk of microbial contamination of aseptically filled biotech products beyond their already low level represent engineering challenges, that don?t really compliment the progress in biotech R&D.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: November 6th 2024 | Updated: November 20th 2024
Automate Aseptic Filling: Closing the System at Full Modularity
Published: November 5th 2024 | Updated: November 20th 2024
Untethered Data: Unifying and Contextualizing Drug Discovery Data
Published: November 8th 2024 | Updated: November 20th 2024
Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification
Published: November 4th 2024 | Updated: November 20th 2024
Strategies for Overcoming Common Challenges in Tech Transfer
